How much does a box of Tivozanib cost?

Tivozanib is an oral, once-daily, new-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent and selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life, designed to improve efficacy and tolerability.

Tivozanib capsule formulation was approved by the U.S. Food and Drug Administration in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after two or more systemic therapies.Sold under the trade name FOTIVDA, it was approved in August 2017 in the European Union and other countries in the territory of its partner EUSA Pharmaceuticals for the treatment of adult patients with advanced RCC. In preclinical models, tivozanib has been shown to significantly reduce the production of regulatory T cells. Tivozanib acts by inhibiting the phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, and VEGFR-3, and inhibits other kinases such as c-kit and platelet-derived growth factor beta (PDGFRβ). The above effects inhibit tumor growth and development and treat renal cell carcinoma.

The original drug Tivozanib has not yet been marketed in the country, so it has not been included in medical insurance. The European version of tivozanib Original drug, specifications1340mcg*21 pills sold overseas may cost around 30,000 yuan per box (the price may fluctuate due to exchange rates), which is relatively expensive. There is currently no generic version of tivozanib available on the market. For more drug information and specific prices, please consult a medical consultant.